Core Viewpoint - The stock of药捷安康-B (02617) surged over 10%, reaching a new high of 78 HKD, driven by its inclusion in the Hong Kong Stock Connect program and the progress of its clinical trials for its core product, Tinengotinib [1] Group 1: Stock Performance -药捷安康-B's stock increased by 10.14%, trading at 69.5 HKD with a transaction volume of 32.81 million HKD [1] Group 2: Market Announcement - The Shanghai Stock Exchange and Shenzhen Stock Exchange announced that药捷安康 has been added to the Hong Kong Stock Connect eligible list, effective from September 8 [1] Group 3: Clinical Development - The company announced the completion of the first patient dosing in an open-label, multicenter Phase II clinical study for its core product, Tinengotinib, in combination with 康方生物科技's 开坦尼 and 依达方 for the treatment of advanced hepatocellular carcinoma [1]

Group 1 - The company reported a revenue of 1.412 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 37.75% [1] - Gross profit reached 1.121 billion RMB, with a year-on-year increase of 18.82% [1] - Research and development expenses amounted to 731 million RMB, reflecting a year-on-year increase of 23.02% [1] Group 2 - Commercial sales revenue was approximately 1.402 billion RMB, a 49.20% increase compared to 939 million RMB in the same period last year, driven by the inclusion of new products in the national medical insurance catalog [1] - The company successfully launched two new products, Yixinning (Inusimab, PCSK9) and Aida Luo (Iroquimab, IL-12/IL-23), contributing to sales growth [1] - The commercial team has expanded to over 1,200 members, focusing on oncology and specialty drugs, enhancing the company's commercial capabilities [1] Group 3 - The company currently has over 50 innovative projects in development across oncology, autoimmune, and metabolic disease fields [2] - Seven self-developed products have been approved for market, with one product under NMPA review and 12 products in Phase III clinical trials [2] - The company's vision is to become a leading global biopharmaceutical enterprise by focusing on innovative drug development and expanding its commercial footprint [2]